ValuEngine upgraded shares of Becton Dickinson and (NYSE:BDX) from a hold rating to a buy rating in a report issued on Tuesday.
A number of other analysts have also recently commented on BDX. BMO Capital Markets initiated coverage on shares of Becton Dickinson and in a research note on Monday, March 5th. They set a market perform rating and a $249.00 price target on the stock. Zacks Investment Research cut shares of Becton Dickinson and from a buy rating to a hold rating in a research note on Tuesday, March 6th. Citigroup upgraded shares of Becton Dickinson and from a neutral rating to a buy rating and upped their price target for the company from $237.00 to $251.00 in a research note on Tuesday, April 10th. Finally, JPMorgan Chase & Co. upgraded shares of Becton Dickinson and from a neutral rating to an overweight rating and set a $175.00 price target on the stock in a research note on Thursday, June 21st. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $237.29.
Shares of BDX stock opened at $239.56 on Tuesday. The company has a market cap of $64.05 billion, a P/E ratio of 25.27, a price-to-earnings-growth ratio of 1.67 and a beta of 1.12. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.12 and a current ratio of 1.70. Becton Dickinson and has a 12 month low of $191.53 and a 12 month high of $248.39.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, May 3rd. The medical instruments supplier reported $2.65 EPS for the quarter, beating the Zacks’ consensus estimate of $2.63 by $0.02. The company had revenue of $4.22 billion for the quarter, compared to analysts’ expectations of $4.12 billion. Becton Dickinson and had a negative net margin of 0.46% and a positive return on equity of 14.27%. Becton Dickinson and’s revenue was up 42.2% compared to the same quarter last year. During the same period in the prior year, the company posted $2.30 EPS. research analysts forecast that Becton Dickinson and will post 10.99 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Friday, June 29th. Shareholders of record on Friday, June 8th were paid a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 1.25%. The ex-dividend date was Thursday, June 7th. Becton Dickinson and’s dividend payout ratio is presently 31.65%.
In other Becton Dickinson and news, insider Alexandre Conroy sold 20,128 shares of the stock in a transaction that occurred on Monday, May 21st. The shares were sold at an average price of $228.74, for a total value of $4,604,078.72. Following the sale, the insider now directly owns 35,583 shares in the company, valued at approximately $8,139,255.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David F. Melcher purchased 500 shares of the firm’s stock in a transaction dated Monday, May 7th. The stock was bought at an average cost of $225.07 per share, for a total transaction of $112,535.00. Following the acquisition, the director now directly owns 2,728 shares in the company, valued at $613,990.96. The disclosure for this purchase can be found here. Corporate insiders own 1.00% of the company’s stock.
Several large investors have recently modified their holdings of BDX. Almanack Investment Partners LLC. bought a new position in shares of Becton Dickinson and in the 4th quarter worth $109,000. BDO Wealth Advisors LLC increased its holdings in shares of Becton Dickinson and by 361.6% in the 1st quarter. BDO Wealth Advisors LLC now owns 577 shares of the medical instruments supplier’s stock worth $125,000 after buying an additional 452 shares during the last quarter. Truewealth LLC bought a new position in shares of Becton Dickinson and in the 4th quarter worth $133,000. Wagner Wealth Management LLC bought a new position in shares of Becton Dickinson and in the 4th quarter worth $154,000. Finally, Icon Wealth Partners LLC bought a new position in shares of Becton Dickinson and in the 4th quarter worth $156,000. 84.08% of the stock is currently owned by hedge funds and other institutional investors.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.